NASDAQ:ACXP
Acurx Pharmaceuticals, Inc. Stock News
$2.25
+0.0900 (+4.17%)
At Close: May 17, 2024
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript
11:19am, Monday, 18'th Mar 2024
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript
STATEN ISLAND, N.Y. , March 4, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibio
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024
07:01am, Tuesday, 23'rd Jan 2024
STATEN ISLAND, N.Y. , Jan. 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ: "ACXP"), a late-stage biopharmaceutical company developing a new class of small mol
Acurx Sell-Off Presents Opportunity Before Upcoming Data Release
12:04pm, Monday, 22'nd Jan 2024
Acurx shares opened ~25% lower on Jan 17th, after releasing positive data suggesting its C. diff antibiotic outperformed standard treatment in restoring the gut microbiome. The decline in share price
Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023
07:01am, Tuesday, 22'nd Aug 2023
STATEN ISLAND, N.Y. , Aug. 22, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023
07:01am, Tuesday, 20'th Jun 2023
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference. STATEN ISLAND, N.Y.
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2022 Earnings Call Transcript
02:20pm, Thursday, 16'th Mar 2023
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q4 2022 Earnings Conference Call March 16, 2023 8:00 AM ET Company Participants Robert Shawah - Co-Founder & Chief Financial Officer David Luci - President &
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023
08:01am, Monday, 16'th Jan 2023
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive question and answer session at the Emerging Growth Conference STATEN ISLAND,
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2022 Earnings Call Transcript
11:14am, Monday, 14'th Nov 2022
Start Time: 08:30 January 1, 0000 8:49 AM ET Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q3 2022 Earnings Conference Call November 14, 2022, 08:30 AM ET Company Participants David Luci - President and
STATEN ISLAND, N.Y. , Nov. 1, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibioti
Acurx Pharmaceuticals, Inc. (ACXP) CEO David Luci on Q2 2022 Results - Earnings Call Transcript
11:53am, Tuesday, 16'th Aug 2022
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q2 2022 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Robert Shawah - CFO David Luci - CEO Conference Call Participants Jim Molloy
STATEN ISLAND, N.Y. , Aug. 4, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibioti
Acurx Pharmaceuticals, Inc.'s (ACXP) CEO David Luci on Q1 2022 Results - Earnings Call Transcript
03:58pm, Wednesday, 11'th May 2022
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Rob Shawah - Chief Financial Officer David Luci - President and Chief Executive
STATEN ISLAND, N.Y. , April 29, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibi
Acurx Pharmaceuticals (NASDAQ:ACXP) Coverage Initiated at Maxim Group
09:12am, Friday, 03'rd Dec 2021 Transcript Daily
Maxim Group started coverage on shares of Acurx Pharmaceuticals (NASDAQ:ACXP) in a research note issued to investors on Monday morning, The Fly reports. The brokerage issued a buy rating and a $12.00 target price on the stock. Acurx Pharmaceuticals stock opened at $4.22 on Monday. The businesss 50-day simple moving average is $4.91. Acurx Pharmaceuticals []